Tadashi Watabe
Associate Professor Osaka University
Prof. Tadashi Watabe is an Associate Professor at the University of Osaka, Japan and a board-certified nuclear medicine physician internationally recognized for advancing theranostics and targeted alpha therapy. He leads investigator-initiated first-in-human clinical trials using astatine-211, including the completed Alpha-T1 trial of [211At]NaAt for radioiodine-refractory thyroid cancer and the ongoing Alpha-PS1 trial of [211At]PSMA-5 for castration-resistant prostate cancer. He also directs clinical studies of emerging PET tracers, including FAPI-74, FBPA, and HCA2969. With more than 180 peer-reviewed publications, his research spans translational radiopharmaceutical development from preclinical innovation to clinical implementation. He serves as Executive Congress Chair of Theranostics World Congress 2027.
Seminars
- Translate novel At-211 compounds from discovery through preclinical development, examining the studies required to build confidence ahead of clinical translation
- Navigate preclinical toxicity & translational considerations when progressing an At- 211 program towards FIH evaluation
- Share lessons from investigator-initiated Phase I development to identify what early-stage RLT developers should consider when designing the next generation of alpha-emitting therapeutics
Novel Target